✦ LIBER ✦

BBS-1 - A novel inhibitor of the β-secretase pathway of Aβ generation in Alzheimer's disease

✍ Scribed by Beka Solomon

Book ID: 118465478
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 41 KB
Volume: 5
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2009.05.471

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

β-arrestin 2 regulates Aβ generation and

β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer’s disease

✍ Thathiah, Amantha; Horre, Katrien; Snellinx, An; Vandewyer, Elke; Huang, Yunhong 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 75 KB

β-Secretase Inhibitors for the Treatment

β-Secretase Inhibitors for the Treatment of Alzheimer’s Disease and Down’s Syndrome

✍ Abdel-Magid, Ahmed F. 📂 Article 📅 2013 🏛 American Chemical Society 🌐 English ⚖ 246 KB

β-secretase as a target for the treatmen

β-secretase as a target for the treatment of Alzheimer's disease

✍ Martin Citron 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 1 views

## Abstract Finding inhibitors of the first step of the amyloid cascade, Aβ~42~ generation, is a major goal of Alzheimer's disease drug development. Two target protease activities, β‐and γ‐secretase, were detected more than 10 years ago but progress in this area has been slow because the enzymes we

ICEBERG: A Novel Inhibitor of Interleuki

ICEBERG: A Novel Inhibitor of Interleukin-1β Generation

✍ Eric W Humke; Stephanie K Shriver; Melissa A Starovasnik; Wayne J Fairbrother; V 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 642 KB

Glycosaminoglycan-induced activation of

Glycosaminoglycan-induced activation of the β-secretase (BACE1) of Alzheimer’s disease

✍ David W. Klaver; Matthew C. J. Wilce; Robert Gasperini; Craig Freeman; John Paul 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 600 KB

Boom in the development of non-peptidic

Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

✍ Romano Silvestri 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

## Abstract β‐Amyloid cleaving enzyme‐1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first non‐peptidomimetic β‐secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non‐